HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides

Current candidate vaccines fail to protect primates against challenge with human immunodeficiency virus (HIV) in the presence of antibody responses; this underlines the importance of studying cell-mediated immunity to HIV and identifying specific epitopes that stimulate cytotoxic T lymphocytes (CTL)...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) 1988-12, Vol.336 (6198), p.484-487
Main Authors: Nixon, Douglas F, Townsend, Alain R. M, Elvin, John G, Rizza, Charles R, Gallwey, John, McMichael, Andrew J
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Acquired Immunodeficiency Syndrome - immunology
AIDS
AIDS/HIV
Antigens, Viral
Biological and medical sciences
DNA, Recombinant
Epitopes - immunology
Fundamental and applied biological sciences. Psychology
Gene Products, gag
HIV Antigens - immunology
HIV Seropositivity
HLA Antigens - immunology
HLA-A Antigens - immunology
HLA-A2 Antigen
HLA-B Antigens - immunology
HLA-B27 Antigen
Human immunodeficiency virus 1
Humans
Immunity, Cellular
Lymphocytes
Medical research
Microbiology
Peptide Fragments - immunology
Peptides
Primates
Replicative cycle, interference, host-virus relations, pathogenicity, miscellaneous strains
Retroviridae Proteins - immunology
T-Lymphocytes, Cytotoxic - immunology
Vaccines
Vaccinia virus
Vaccinia virus - immunology
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current candidate vaccines fail to protect primates against challenge with human immunodeficiency virus (HIV) in the presence of antibody responses; this underlines the importance of studying cell-mediated immunity to HIV and identifying specific epitopes that stimulate cytotoxic T lymphocytes (CTL). Using a recombinant vaccinia virus to express the gag protein of HIV-1 we found HLA class-I-restricted gag-specific CTL in thirteen out of fifteen healthy HIV seropositive patients. We then used short synthetic peptides in the lysis assay to screen for gag CTL epitopes. In one patient we have identified a peptide in p24 that is recognized by CTL in association with HLA-B27. This peptide, and further peptide sequences defined by these methods, could be incorporated in vaccines designed to induce cell-mediated immunity against HIV.
ISSN:0028-0836
1476-4687
DOI:10.1038/336484a0